Diabetes Mellitus Clinical Trial
— QoC SCPOfficial title:
Evaluation of Quality of Care - Shared-Care Programme, HA
| Verified date | November 2017 |
| Source | The University of Hong Kong |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Diabetes mellitus (DM) and hypertension (HT) are major causes of morbidity and among the top
10 causes of deaths in Hong Kong in 2008 (Department of Health 2009). The Hospital Authority
(HA) has initiated service improvement through introducing the shared-care (SC) programme to
improve the quality of care (QOC) for DM and HT patients. The evaluation on the QOC is an
essential part of the programme in order to inform future policy. The Family Medicine Unit
(FMU) of the University of Hong Kong (HKU) has been appointed by the HA to carry out the
evaluation of the QOC of the programme.
The Action Learning and Audit Spiral methodologies to measure whether the target standard of
care intended by the SC programme is achieved. Each SC participating clinic and private
medical practitioner (PMP) will be invited to complete a structured evaluation questionnaire.
The data of all patients who have enrolled into the programme will be included in the
evaluation on the process and outcomes of care. A hundred and thirty participants will be
followed up by telephone to evaluate the effect of the programme in quality of life (QOL),
patient enablement, and global rating of change in health condition at baseline and 6 months
after enrolment. Data on the process of care will be retrieved from the HA medical records.
Main Outcome Measures: The primary outcomes are the proportion of participants who received
the criterion process of care and achieved a HbA1c level <7.5%.
Data Analysis: Descriptive statistics on proportions of clinics or subjects meeting the
quality of care criteria will be calculated. The outcomes of SC patients will be compared at
6, 12, 24, 36 and 48 months by paired sample t-test. The outcomes between SC patients and
control group will be compared by independent sample t-test or Chi-square test.
Hypothesis: The QOC of the SC programme will be determined. Areas of deficiency and possible
areas for quality enhancement will be identified. The results of this study will provide
empirical evidence on whether the HA's SC programme can achieve equivalent QOC as the usual
HA care for diabetes mellitus (DM) patients. The information will be used to guide service
planning and policy decision making.
| Status | Completed |
| Enrollment | 620 |
| Est. completion date | September 2015 |
| Est. primary completion date | September 2015 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Patients with diabetes mellitus who have received care at the specialist outpatient clinic (SOPC)for at least 2 years, stratified to be of low risk and have normal renal function as defined by the plasma creatinine level. Exclusion Criteria: - Patients will be excluded if they are stratified to be at high cardiovascular risk or are suffering end stage renal failure, on dialysis or after transplantation, or on insulin, or do not give consent to be transferred. |
| Country | Name | City | State |
|---|---|---|---|
| Hong Kong | The University of Hong Kong | Hong Kong | Hksar |
| Lead Sponsor | Collaborator |
|---|---|
| The University of Hong Kong | Hospital Authority, Hong Kong |
Hong Kong,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change of the proportion of clinics that have satisfied each of the structure criteria. | December, 2010; December, 2011; December, 2012; December, 2013; December, 2014 | ||
| Primary | Change of the proportion of patients who have received with the SC criterion process of care. | June, 2011; December, 2011; December, 2012; December, 2013; December, 2014 | ||
| Primary | Change of the proportion of patients who have achieved a HbA1c <7.5%. | June, 2011; December, 2011; December, 2012; December, 2013; December, 2014 | ||
| Secondary | Low-density lipoprotein (LDL) | Baseline, 6, 12, 24, 36 and 48 months after enrollment. | ||
| Secondary | Blood pressure (BP) | Baseline, 6, 12, 24, 36 and 48 months after enrollment. | ||
| Secondary | Body mass index (BMI) | Baseline, 6, 12, 24, 36 and 48 months after enrollment. | ||
| Secondary | Cardiovascular complications | Baseline, 6, 12, 24, 36 and 48 months after enrollment. | ||
| Secondary | Patient reported outcomes (PRO) measured by the change in Short Form-12 version 2 (SF-12v2) scores at 6 months. | Baseline and 6 months after the first administration of questionnaire. | ||
| Secondary | Patient reported outcomes (PRO) measured by the change in the Patient Enablement Instrument (PEI) scores at 6 months. | Baseline and 6 months after the first administration of questionnaire. | ||
| Secondary | Patient reported outcomes (PRO) measured by the change in the Global Rating Scale (GRS) at 6 months. | Baseline and 6 months after the first administration of questionnaire. | ||
| Secondary | Service utilization outcomes measured by General Outpatient Clinics (GOPC) attendance rates at baseline and 12, 24, 36 and 48 months after enrollment. | Baseline, 12, 24, 36 and 48 months after enrollment | ||
| Secondary | Service utilization outcomes measured by specialist outpatient clinic (SOPC) attendance rates at baseline and 12, 24, 36 and 48 months after enrollment. | Baseline, 12, 24, 36 and 48 months after enrollment | ||
| Secondary | Service utilization outcomes measured by accident & emergency (A&E) attendance rates at baseline and 12, 24, 36 and 48 months after enrollment. | Baseline, 12, 24, 36 and 48 months after enrollment | ||
| Secondary | Service utilization outcomes measured by hospital attendance rates at baseline and 12, 24, 36 and 48 months after enrollment. | Baseline, 12, 24, 36 and 48 months after enrollment |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |